Attached files
file | filename |
---|---|
EX-3.1 - CERTIFICATE OF AMENDMENT TO THE COMPANY'S CERTIFICATE OF INCORPORATION - AEOLUS PHARMACEUTICALS, INC. | v210198_ex3-1.htm |
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported): February 7, 2011
AEOLUS PHARMACEUTICALS,
INC.
(Exact
name of registrant as specified in its charter)
Delaware
(State or
other jurisdiction of incorporation)
0-50481
(Commission
File Number)
|
56-1953785
(IRS
Employer Identification No.)
|
26361
Crown Valley Parkway, Suite 150
Mission
Viejo, California 92691
(Address
of Principal Executive Offices, Including Zip Code)
949-481-9825
(Registrant’s
Telephone Number, Including Area Code)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General
Instruction A.2. below):
o
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
Item
5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal
Year.
Effective
February 7, 2011, Aeolus Pharmaceuticals, Inc. (the “Company”) amended its
certificate of incorporation pursuant to a certificate of amendment to increase
the number of authorized shares of preferred stock designated as “Series B
Convertible Preferred Stock” from 600,000 shares to 1,600,000
shares.
A copy of
the certificate of amendment is filed as Exhibit 3.1 to this Current Report on
Form 8-K, which is incorporated herein by reference.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits.
Exhibit
#
|
Description
|
|
3.1
|
Certificate
of Amendment to the Company’s Certificate of
Incorporation.
|
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this Report to be signed on its behalf by the undersigned hereunto
duly authorized.
Date: February
7, 2011
|
AEOLUS
PHARMACEUTICALS, INC.
|
||
/s/
John L. McManus
|
|||
John
L. McManus
|
|||
President
and Chief Executive Officer
|
|||